For men newly diagnosed with prostate cancer, a significant shift in treatment strategy may be on the horizon. Research published in The Lancet Oncology suggests that treatment with PSMA therapy – a targeted radiation approach – can delay the need for hormone therapy, a common but often debilitating component of prostate cancer care, by as much as 20 months. This finding offers a potential pathway to improve quality of life and postpone the onset of challenging side effects for many patients.
Prostate cancer remains a leading health concern for men worldwide. According to the American Cancer Society, about 1 in 8 men will be diagnosed with prostate cancer during their lifetime. While treatment options have expanded in recent years, including surgery, radiation, chemotherapy, and hormone therapy, each carries its own set of potential drawbacks. Hormone therapy, in particular, while effective at slowing cancer growth, can cause side effects mimicking menopause, such as hot flashes, fatigue, and loss of muscle mass. The prospect of delaying or even avoiding these effects is a major focus of ongoing research.
The study, led by researchers at Radboud University Medical Center in the Netherlands, focused on men with limited metastatic prostate cancer – meaning the cancer had spread to a small number of sites, but not extensively. Fifty-eight men participated in the randomized, phase 2 trial. Participants had already undergone initial treatment, either targeted radiation or surgery, and were awaiting the standard next step: hormone therapy. Half of the group received PSMA therapy immediately, while the other half served as a control group, receiving PSMA therapy only when their disease progressed. All participants were monitored for at least two years.
How PSMA Therapy Works
PSMA (prostate-specific membrane antigen) is a protein found in high levels on prostate cancer cells. PSMA therapy utilizes a radioactive substance attached to a molecule that specifically binds to this protein. This allows the radiation to target and destroy cancer cells while minimizing damage to surrounding healthy tissue. The therapy, administered through intravenous infusion, has already shown promise in men with advanced prostate cancer who have exhausted other treatment options, offering both prolonged survival and improved quality of life. The full study details are available in The Lancet Oncology.
Significant Delay in Hormone Therapy
The results of the Dutch study were compelling. After 27 months, 52% of the men who received PSMA therapy initially had experienced disease progression, compared to 97% in the control group. This translated to an average delay of 20 months before hormone therapy became necessary. Importantly, the PSMA therapy itself was well-tolerated, with few reported side effects. Researchers also observed that, in some cases, the PSMA therapy reduced the cancer burden enough to make patients eligible for further targeted radiation therapy, potentially extending the time before hormone therapy was needed even further.
“We see that You can postpone more burdensome hormone therapy,” explained Bastiaan Privé, the study’s first author, in a statement from Radboudumc. “PSMA therapy sometimes reduces the cancer enough for men to become once again eligible for targeted radiation. This may further contribute to delaying hormone treatment in the future.”
Implications for Future Treatment
The study’s findings suggest that PSMA therapy could play a significant role in the treatment of limited metastatic prostate cancer, offering a valuable option for men seeking to avoid or delay the side effects of hormone therapy. James Nagarajah, a Nuclear Medicine Physician and project leader, emphasized the growing desire among patients to avoid hormone therapy due to its impact on quality of life. “More and more men want to avoid hormone therapy because of the unpleasant side effects that can occur,” he said.
While these results are promising, it’s vital to note that this was a phase 2 study, meaning it was designed to assess the safety and efficacy of the treatment in a smaller group of patients. Larger, phase 3 trials are now needed to confirm these findings and establish PSMA therapy as a standard of care. Researchers are also investigating whether PSMA therapy could eventually be used as an alternative to hormone therapy altogether, though that remains a longer-term goal.
Approximately 15,000 men are diagnosed with prostate cancer annually in the Netherlands, according to Radboud University Medical Center. The potential to improve treatment outcomes and quality of life for these men – and for the millions more diagnosed worldwide – makes this research a significant step forward in the fight against prostate cancer.
The next step in validating these findings will be the completion of ongoing phase 3 clinical trials, with results expected in the coming years. Patients interested in learning more about PSMA therapy and potential clinical trial opportunities should discuss their options with their oncologist.
Have you or a loved one been affected by prostate cancer? Share your thoughts and experiences in the comments below. Please also share this article with anyone who might find this information helpful.
